Getting to the heart of the matter: insights from a new infective endocarditis prevention statement

Dr. Jason Goodchild, Vice President of Clinical Affairs at Premier Dental Products Company, and Dr. Mark Donaldson, Associate Principal in Pharmacy Advisory Solutions at Vizient discuss the merits of a recent statement on antibiotic prophylaxis for infective endocarditis with host Gretchen Brummel.

 

Guest speakers:

Jason Goodchild, DMD

Vice President of Clinical Affairs

Premier Dental Products Company

 

Mark Donaldson, BSP, ACPR, PHARMD, FASHP, FACHE

Associate Principal, Pharmacy Advisory Solutions

Vizient

 

Moderator:

Gretchen Brummel, PharmD, BCPS

Pharmacy Executive Director

Vizient Center for Pharmacy Practice Excellence

 

Show Notes:

[00:53-1:55] Antibiotic prophylaxis against infective endocarditis as an important tool

[01:56-2:48] Risks of over- or underutilization of this treatment modality

[02:49-4:52] History of the guidelines

[04:53-5:48] New statement impacts moving forward

[05:49-8:49] Doxycycline as alternative to clindamycin in penicillin-allergic patients

[08:50-9:47] The rationale to abandon clindamycin

[09:48-11:49] How clindamycin compares to other agents

[11:50-12:59] The bottom line

 

Links | Resources:

Prevention of Viridans group Streptococcal infective endocarditis: a scientific statement from the American Heart Association: Click here

Prevention of infective endocarditis: guidelines from the American Heart Association: Click here

Antibiotic prophylaxis guidelines: is there new information for 2021? Click here

 

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Google Podcasts

Spotify

Stitcher

Android

RSS Feed